Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors | Zendy

Kohei Fujita | Zendy; Yuki Yamamoto | Zendy; Osamu Kanai | Zendy; Misato Okamura | Zendy; Masayuki Hashimoto | Zendy; Koichi Nakatani | Zendy; Satoru Sawai | Zendy; Tadashi Mio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Author(s) -

Kohei Fujita,

Yuki Yamamoto,

Osamu Kanai,

Misato Okamura,

Masayuki Hashimoto,

Koichi Nakatani,

Satoru Sawai,

Tadashi Mio

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa126

Subject(s) - medicine , tuberculosis , immunotherapy , lung cancer , incidence (geometry) , immunology , active tuberculosis , immune system , oncology , mycobacterium tuberculosis , pathology , physics , optics

Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immunotherapy at our institution. In patients with a positive interferon-gamma release assay status before ICI therapy, physicians should pay close attention to developing tuberculosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research